Literature DB >> 25947025

[A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel].

Taku Matsuo1, Yukiko Nakamura, Koji Suzuki.   

Abstract

A 73-year-old woman had received 9 months of chemotherapy with nab-paclitaxel for locally advanced breast cancer. During the treatment, she was well and showed no major side effects except for alopecia and arthralgia. The tumor showed a tendency to reduction. However, chemotherapy was discontinued because of liver dysfunction. MRCP and ERCP demonstrated multiple stenoses of the hepatic ducts and the intrahepatic bile ducts. We diagnosed chemotherapy-induced sclerosing cholangitis caused by nab-paclitaxel. Treatment with ursodeoxycholic acid and steroid was ineffective. We added bezafibrate, which resulted in a gradual improvement in liver function. To the best of our knowledge, this is the first reported case of nab-paclitaxel-induced secondary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25947025     DOI: 10.11405/nisshoshi.112.888

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  2 in total

1.  Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.

Authors:  Borui Pi; Jin Wang; Yifan Tong; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

2.  Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy.

Authors:  Akira Kusakabe; Kazuyoshi Ohkawa; Nobuyasu Fukutake; Mitsuru Sakakibara; Toshihiro Imai; Yutaro Abe; Ryoji Takada; Kenji Ikezawa; Takatoshi Nawa; Reiko Ashida; Toshihiro Kimura; Shigenori Nagata; Kazuhiro Katayama
Journal:  ACG Case Rep J       Date:  2019-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.